Genentech Files IND For tPA Follow-up

12 December 1994

Genentech has filed an Investigational New Drug Application for a follow-up to its tissue plasminogen activator (tPA) thrombolytic drug Activase (alteplase). Clinical trials of the new agent, called TNK, are expected to begin in early 1995. Preliminary data suggest that TNK may dissolve blood clots even faster than tPA. The company says it has also advanced an oral glycoprotein IIb/IIIa antagonist into full development to prevent vacular events such as myocardial infarction and stroke.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight